U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C21H25ClN2O3
Molecular Weight 388.8885
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CETIRIZINE

SMILES

c1ccc(cc1)C(c2ccc(cc2)Cl)N3CCN(CC3)CCOCC(=O)O

InChI

InChIKey=ZKLPARSLTMPFCP-UHFFFAOYSA-N
InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)

HIDE SMILES / InChI

Molecular Formula C21H25ClN2O3
Molecular Weight 388.8885
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: https://www.drugs.com/pro/cetirizine.html

Cetirizine, a human metabolite of hydroxyzine, is an antihistamine; its principal effects are mediated via selective inhibition of peripheral H1 receptors. It is indicated for the relief of nasal and non-nasal symptoms associated with seasonal or perennial allergic rhinitis, hay fever and chronic idiopathic urticaria. Commonly reported adverse reactions of cetirizine include headache, dry mouth and drowsiness or fatigue. Pharmacokinetic interaction studies with Cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and azithromycin. No interactions were observed.

CNS Activity

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ZYRTEC HIVES RELIEF

Approved Use

Tablets should be administered when both the antihistaminic properties of cetirizine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired.

Launch Date

818380800000
Palliative
ZYRTEC HIVES RELIEF

Approved Use

Tablets should be administered when both the antihistaminic properties of cetirizine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired.

Launch Date

818380800000
Palliative
ZYRTEC HIVES RELIEF

Approved Use

Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: •runny nose •sneezing •itchy, watery eyes •itching of the nose or throat

Launch Date

818380800000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
311 ng/mL
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CETIRIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
978.4 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CETIRIZINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6375.6 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CETIRIZINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.3 h
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CETIRIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6.9 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CETIRIZINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
7%
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CETIRIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources:
unhealthy, 18 months
Health Status: unhealthy
Age Group: 18 months
Sex: M
Sources:
270 mg single, oral
Overdose
Dose: 270 mg
Route: oral
Route: single
Dose: 270 mg
Sources:
unhealthy, 18 years
Health Status: unhealthy
Age Group: 18 years
Sex: F
Sources:
Other AEs: Metabolic acidosis, Hypokalemia...
Other AEs:
Metabolic acidosis (grade 5, 1 patient)
Hypokalemia (grade 5, 1 patient)
Sources:
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 18 years
Health Status: unhealthy
Age Group: 18 years
Sex: F
Sources:
Disc. AE: Delusions, Depression...
AEs leading to
discontinuation/dose reduction:
Delusions (1 patient)
Depression (1 patient)
Sources:
2.5 mg 1 times / day multiple, oral
Dose: 2.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 1 times / day
Sources:
unhealthy, 23 months
Health Status: unhealthy
Age Group: 23 months
Sex: M
Sources:
Disc. AE: Insomnia...
AEs leading to
discontinuation/dose reduction:
Insomnia (1 patient)
Sources:
10 mg single, intravenous
Recommended
unhealthy, 39 years
Other AEs: Dyspepsia, Feeling hot...
Other AEs:
Dyspepsia (1%)
Feeling hot (1%)
Dysgeusia (1%)
Headache (1%)
Paresthesia (1%)
Presyncope (1%)
Hyperhidrosis (1%)
Sources:
60 mg single, oral
Overdose
Dose: 60 mg
Route: oral
Route: single
Dose: 60 mg
Sources:
healthy, 4 years
Health Status: healthy
Age Group: 4 years
Sex: M
Sources:
Other AEs: Drowsiness, Sedation...
Other AEs:
Drowsiness (severe, 1 patient)
Sedation (1 patient)
Sources:
50 mg 1 times / day multiple, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 46 years
Health Status: unhealthy
Age Group: 46 years
Sex: M
Sources:
5 mg 1 times / day multiple, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 6 years
Health Status: unhealthy
Age Group: 6 years
Sex: M
Sources:
Disc. AE: Dystonic reaction...
AEs leading to
discontinuation/dose reduction:
Dystonic reaction (1 patient)
Sources:
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sex: M+F
Sources:
Other AEs: Somnolence, Fatigue...
Other AEs:
Somnolence (13.7%)
Fatigue (5.9%)
Dry mouth (5%)
Dizziness (2%)
Pharyngitis (2%)
Sources:
0.24 % 2 times / day multiple, ophthalmic
Recommended
unhealthy, adult
Other AEs: Ocular hyperemia, Visual acuity reduced...
AEs

AEs

AESignificanceDosePopulation
Hypokalemia grade 5, 1 patient
270 mg single, oral
Overdose
Dose: 270 mg
Route: oral
Route: single
Dose: 270 mg
Sources:
unhealthy, 18 years
Health Status: unhealthy
Age Group: 18 years
Sex: F
Sources:
Metabolic acidosis grade 5, 1 patient
270 mg single, oral
Overdose
Dose: 270 mg
Route: oral
Route: single
Dose: 270 mg
Sources:
unhealthy, 18 years
Health Status: unhealthy
Age Group: 18 years
Sex: F
Sources:
Delusions 1 patient
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 18 years
Health Status: unhealthy
Age Group: 18 years
Sex: F
Sources:
Depression 1 patient
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 18 years
Health Status: unhealthy
Age Group: 18 years
Sex: F
Sources:
Insomnia 1 patient
Disc. AE
2.5 mg 1 times / day multiple, oral
Dose: 2.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 1 times / day
Sources:
unhealthy, 23 months
Health Status: unhealthy
Age Group: 23 months
Sex: M
Sources:
Dysgeusia 1%
10 mg single, intravenous
Recommended
unhealthy, 39 years
Dyspepsia 1%
10 mg single, intravenous
Recommended
unhealthy, 39 years
Feeling hot 1%
10 mg single, intravenous
Recommended
unhealthy, 39 years
Headache 1%
10 mg single, intravenous
Recommended
unhealthy, 39 years
Hyperhidrosis 1%
10 mg single, intravenous
Recommended
unhealthy, 39 years
Paresthesia 1%
10 mg single, intravenous
Recommended
unhealthy, 39 years
Presyncope 1%
10 mg single, intravenous
Recommended
unhealthy, 39 years
Sedation 1 patient
60 mg single, oral
Overdose
Dose: 60 mg
Route: oral
Route: single
Dose: 60 mg
Sources:
healthy, 4 years
Health Status: healthy
Age Group: 4 years
Sex: M
Sources:
Drowsiness severe, 1 patient
60 mg single, oral
Overdose
Dose: 60 mg
Route: oral
Route: single
Dose: 60 mg
Sources:
healthy, 4 years
Health Status: healthy
Age Group: 4 years
Sex: M
Sources:
Dystonic reaction 1 patient
Disc. AE
5 mg 1 times / day multiple, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 6 years
Health Status: unhealthy
Age Group: 6 years
Sex: M
Sources:
Somnolence 13.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sex: M+F
Sources:
Dizziness 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sex: M+F
Sources:
Pharyngitis 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sex: M+F
Sources:
Dry mouth 5%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sex: M+F
Sources:
Fatigue 5.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sex: M+F
Sources:
Visual acuity reduced 0.6%
0.24 % 2 times / day multiple, ophthalmic
Recommended
unhealthy, adult
Ocular hyperemia 2%
0.24 % 2 times / day multiple, ophthalmic
Recommended
unhealthy, adult
Conjunctival hyperemia 5.3%
0.24 % 2 times / day multiple, ophthalmic
Recommended
unhealthy, adult
PubMed

PubMed

TitleDatePubMed
The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare.
2001
Efficacy and safety of levocetirizine in seasonal allergic rhinitis.
2001
[The effect of second generation histamine antagonists on the heart].
2001
Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis.
2001
Cetirizine reduces the number of tryptase-positive mast cells in psoriatic patients: a double-blind controlled study.
2001
Treatment of severe seasonal rhinoconjunctivitis by a combination of azelastine nasal spray and eye drops: a double-blind, double-placebo study.
2001
[Eosinophilic pustular folliculitis in childhood].
2001 Aug
Stability of cetirizine dihydrochloride in solid state.
2001 Jan-Feb
Double-blind multicenter study on the efficacy and tolerability of cetirizine compared with oxatomide in chronic idiopathic urticaria in preschool children.
2001 Jul
Severe hepatitis in a patient taking cetirizine.
2001 Jul 17
Antihistamines and the torsade de point in children with allergic rhinitis.
2001 Jul-Aug
Burn wound itch control using H1 and H2 antagonists.
2001 Jul-Aug
Stanozolol in chronic urticaria: a double blind, placebo controlled trial.
2001 Jun
Stability indicating HPTLC method for the simultaneous determination of pseudoephedrine and cetirizine in pharmaceutical formulations.
2001 Jun
Distributions of results of cetirizine dihydrochloride assay in bulk material.
2001 Jun 19
[Co-administration of histamine H1 antagonist and oral anticoagulants].
2001 Jun-Jul
The comparison of the efficacy of fluticasone propionate with cetirizine in perennial allergic rhinitis.
2001 Mar-Apr
Lipophilicity behaviour of the Zwitterionic antihistamine cetirizine in phosphatidylcholine liposomes/water systems.
2001 May
Acute urticaria with elevated circulating interleukin-6 is resistant to anti-histamine treatment.
2001 May
[The course of allergy: principles for early diagnosis, prevention and early therapy of allergic diseases].
2001 May
A descriptive analysis of the use and cost of new-generation antihistamines in the treatment of allergic rhinitis: a retrospective database analysis.
2001 May
A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults.
2001 May-Jun
Efficacy and safety of an oral formulation of cetirizine and prolonged-release pseudoephedrine versus xylometazoline nasal spray in nasal congestion.
2001 Nov
Multiwavelength spectrophotometric resolution of the micro-equilibria of cetirizine.
2001 Oct
Preclinical comparison of ebastine and other second generation H1-antihistamines.
2001 Oct
Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers.
2001 Oct
Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis.
2001 Oct
The costs of nonsedating antihistamine therapy for allergic rhinitis in managed care: an updated analysis.
2001 Oct
Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid.
2001 Oct
Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin.
2001 Oct
Cetirizine inhibits skin reactions but not mediator release in immediate and developing late-phase allergic cutaneous reactions. A double-blind, placebo-controlled study.
2001 Sep
Potential cardiac toxicity of H1-antihistamines.
2002
Pharmacokinetics of cetirizine in tear fluid after a single oral dose.
2002
Displacement of histamine from liver cells and cell components by ligands for cytochromes P450.
2002
Effects of antihistamines on leukotriene and cytokine release from dispersed nasal polyp cells.
2002
[The first case of lasting pigmented toxidermia induced by cetirizine (Zyrtec, Virlix) and ticlopidine].
2002 Apr
Acute hepatitis associated with cetirizine intake.
2002 Apr
Are antihistamines useful in managing asthma?
2002 Feb
A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects.
2002 Feb
Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194).
2002 Feb
Cardiotoxicity of new antihistamines and cisapride.
2002 Feb 28
Titrimetric and spectrophotometric assay of some antihistamines through the determination of the chloride of their hydrochlorides.
2002 Jan
Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis.
2002 Jan 19
Cetirizine decreases interleukin-4, interleukin-5, and interferon-gamma gene expressions in nasal-associated lymphoid tissue of sensitized mice.
2002 Jan-Feb
Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers.
2002 Jul
Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes.
2002 Jul 1
Comparative activity of cetirizine and mizolastine on histamine-induced skin wheal and flare responses at 24 h.
2002 Mar
Gateways to clinical trials.
2002 May
Urticarial intolerance reaction to cetirizine.
2002 May
Development and validation of a HPLC method for the determination of cetirizine in pharmaceutical dosage forms.
2002 May
Patents

Sample Use Guides

1 to 2 tablets once daily depending upon severity of symptoms; do not take more than 2 tablets in 24 hours
Route of Administration: Oral
In Vitro Use Guide
Cetirizine (10 micrograms/ml) significantly enhanced IL-1 release by human monocytes stimulated by a weak LPS concentration (1 microgram/ml) but could not modify the maximal increase of IL-1 release induced by 10 micrograms/ml of LPS. It did not exert any effect on resting cells. Cetirizine (0.1-10 micrograms/ml) enhanced PGE2 release by resting human monocytes. Concentrations of 1 and 10 micrograms/ml enhanced PGE2 release by LPS-stimulated monocytes, and by healthy and inflamed rat macrophages.
Substance Class Chemical
Created
by admin
on Fri Jun 25 22:45:46 UTC 2021
Edited
by admin
on Fri Jun 25 22:45:46 UTC 2021
Record UNII
YO7261ME24
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CETIRIZINE
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
CETIRIZINE [MI]
Common Name English
(+/-)-(2-(4-(P-CHLORO-A-PHENYLBENZYL)-1-PIPERAZINYL)ETHOXY)ACETIC ACID
Common Name English
CETIRIZINE [HSDB]
Common Name English
AC-170
Code English
CETIRIZINE [INN]
Common Name English
ACETIC ACID, (2-(4-((4-CHLOROPHENYL)PHENYLMETHYL)-1-PIPERAZINYL)ETHOXY)-, (+/-)-
Common Name English
CETIRIZINE [WHO-DD]
Common Name English
CETIRIZINE [VANDF]
Common Name English
CETIDERM
Brand Name English
Classification Tree Code System Code
LIVERTOX 180
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
NCI_THESAURUS C29578
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
NDF-RT N0000175587
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
WHO-VATC QR06AE07
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
NDF-RT N0000000190
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
WHO-ATC R06AE07
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL1000
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
PRIMARY
WIKIPEDIA
CETIRIZINE
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
PRIMARY
LACTMED
Cetirizine
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
PRIMARY
EPA CompTox
83881-51-0
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
PRIMARY
DRUG BANK
DB00341
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
PRIMARY
INN
5520
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
PRIMARY
MERCK INDEX
M3291
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
PRIMARY Merck Index
RXCUI
20610
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
PRIMARY RxNorm
PUBCHEM
2678
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
PRIMARY
EVMPD
SUB07451MIG
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
PRIMARY
DRUG CENTRAL
581
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
PRIMARY
CAS
83881-51-0
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
PRIMARY
NCI_THESAURUS
C1042
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
PRIMARY
MESH
D017332
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
PRIMARY
IUPHAR
1222
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
PRIMARY
HSDB
7739
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
PRIMARY
FDA UNII
YO7261ME24
Created by admin on Fri Jun 25 22:45:47 UTC 2021 , Edited by admin on Fri Jun 25 22:45:47 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
TRANSPORTER -> SUBSTRATE
BINDER->LIGAND
TRANSPORTER -> INHIBITOR
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
Related Record Type Details
PARENT -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC